(CHE) Chemed - Overview

Sector: Healthcare | Industry: Medical Care Facilities | Exchange: NYSE (USA) | Market Cap: 5.684m USD | Total Return: -30.5% in 12m

Healthcare, Plumbing, Restoration
Total Rating 44
Safety 84
Buy Signal -0.16
Medical Care Facilities
Industry Rotation: -11.8
Market Cap: 5.68B
Avg Turnover: 105M USD
ATR: 2.75%
Peers RS (IBD): 17.7
Risk 5d forecast
Volatility25.6%
Rel. Tail Risk-11.6%
Reward TTM
Sharpe Ratio-1.11
Alpha-47.92
Character TTM
Beta0.327
Beta Downside0.291
Drawdowns 3y
Max DD42.88%
CAGR/Max DD-0.24
EPS (Earnings per Share) EPS (Earnings per Share) of CHE over the last years for every Quarter: "2021-03": 4.44, "2021-06": 4.6, "2021-09": 5.06, "2021-12": 5.25, "2022-03": 4.79, "2022-06": 4.84, "2022-09": 4.74, "2022-12": 5.39, "2023-03": 4.82, "2023-06": 4.71, "2023-09": 5.32, "2023-12": 6.6, "2024-03": 5.2, "2024-06": 5.47, "2024-09": 5.64, "2024-12": 6.83, "2025-03": 5.63, "2025-06": 4.27, "2025-09": 5.27, "2025-12": 6.42, "2026-03": 0,
EPS CAGR: -46.08%
EPS Trend: -34.0%
Last SUE: -4.00
Qual. Beats: 0
Revenue Revenue of CHE over the last years for every Quarter: 2021-03: 527.36, 2021-06: 532.256, 2021-09: 538.667, 2021-12: 540.978, 2022-03: 530.549, 2022-06: 531.288, 2022-09: 526.472, 2022-12: 546.654, 2023-03: 560.157, 2023-06: 553.816, 2023-09: 564.532, 2023-12: 585.912, 2024-03: 589.233, 2024-06: 595.88, 2024-09: 606.181, 2024-12: 639.993, 2025-03: 646.943, 2025-06: 618.798, 2025-09: 624.9, 2025-12: 639.337, 2026-03: null,
Rev. CAGR: 5.10%
Rev. Trend: 96.1%
Last SUE: -4.00
Qual. Beats: 0

Warnings

No concerns identified

Tailwinds

No distinct edge detected

Description: CHE Chemed

Chemed Corporation (CHE) operates in two distinct segments: healthcare and plumbing/drainage.

The VITAS segment provides hospice and palliative care, utilizing a team of medical professionals and support staff. This business model focuses on end-of-life care, a specialized area within healthcare services.

The Roto-Rooter segment offers plumbing, drain cleaning, and water restoration services to both residential and commercial clients. This segment operates through a combination of company-owned branches, independent contractors, and franchisees, a common structure in service industries.

For more detailed analysis, consider exploring ValueRays comprehensive reports.

Headlines to Watch Out For
  • VITAS hospice admissions and average daily census drive revenue
  • Roto-Rooter service demand impacts plumbing segment growth
  • Healthcare regulatory changes pose significant compliance risks
  • Labor costs for medical and service staff influence profitability
  • Interest rate fluctuations affect debt servicing and expansion plans
Piotroski VR‑10 (Strict) 8.0
Net Income: 265.2m TTM > 0 and > 6% of Revenue
FCF/TA: 0.20 > 0.02 and ΔFCF/TA -2.21 > 1.0
NWC/Revenue: 0.61% < 20% (prev 4.49%; Δ -3.87% < -1%)
CFO/TA 0.24 > 3% & CFO 388.3m > Net Income 265.2m
Net Debt (80.2m) to EBITDA (423.9m): 0.19 < 3
Current Ratio: 1.05 > 1.5 & < 3
Outstanding Shares: last quarter (14.0m) vs 12m ago -6.66% < -2%
Gross Margin: 31.14% > 18% (prev 0.35%; Δ 3.08k% > 0.5%)
Asset Turnover: 152.9% > 50% (prev 145.7%; Δ 7.22% > 0%)
Interest Coverage Ratio: 109.0 > 6 (EBITDA TTM 423.9m / Interest Expense TTM 3.29m)
Altman Z'' 10.00
A: 0.01 (Total Current Assets 302.6m - Total Current Liabilities 287.1m) / Total Assets 1.64b
B: 1.80 (Retained Earnings 2.96b / Total Assets 1.64b)
C: 0.22 (EBIT TTM 359.1m / Avg Total Assets 1.65b)
D: 4.53 (Book Value of Equity 3.00b / Total Liabilities 660.6m)
Altman-Z'' Score: 12.16 = AAA
Beneish M -2.89
DSRI: 1.03 (Receivables 182.6m/171.2m, Revenue 2.53b/2.43b)
GMI: 1.13 (GM 31.14% / 35.14%)
AQI: 1.08 (AQ_t 0.61 / AQ_t-1 0.57)
SGI: 1.04 (Revenue 2.53b / 2.43b)
TATA: -0.08 (NI 265.2m - CFO 388.3m) / TA 1.64b)
Beneish M-Score: -2.89 (Cap -4..+1) = A
What is the price of CHE shares? As of April 09, 2026, the stock is trading at USD 395.25 with a total of 295,203 shares traded.
Over the past week, the price has changed by +4.68%, over one month by -2.04%, over three months by -11.90% and over the past year by -30.53%.
Is CHE a buy, sell or hold? Chemed has received a consensus analysts rating of 4.67. Therefore, it is recommended to buy CHE.
  • StrongBuy: 2
  • Buy: 1
  • Hold: 0
  • Sell: 0
  • StrongSell: 0
What are the forecasts/targets for the CHE price?
Analysts Target Price 443 12.1%
Chemed (CHE) - Fundamental Data Overview as of 09 April 2026
P/E Trailing = 21.1962
P/E Forward = 16.1031
P/S = 2.2468
P/B = 5.3492
P/EG = 1.6113
Revenue TTM = 2.53b USD
EBIT TTM = 359.1m USD
EBITDA TTM = 423.9m USD
Long Term Debt = 143.8m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 51.9m USD (from shortTermDebt, last quarter)
Debt = 154.8m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 80.2m USD (from netDebt column, last quarter)
Enterprise Value = 5.76b USD (5.68b + Debt 154.8m - CCE 74.5m)
Interest Coverage Ratio = 109.0 (Ebit TTM 359.1m / Interest Expense TTM 3.29m)
EV/FCF = 17.71x (Enterprise Value 5.76b / FCF TTM 325.5m)
FCF Yield = 5.65% (FCF TTM 325.5m / Enterprise Value 5.76b)
FCF Margin = 12.86% (FCF TTM 325.5m / Revenue TTM 2.53b)
Net Margin = 10.48% (Net Income TTM 265.2m / Revenue TTM 2.53b)
Gross Margin = 31.14% ((Revenue TTM 2.53b - Cost of Revenue TTM 1.74b) / Revenue TTM)
Gross Margin QoQ = 32.22% (prev 28.91%)
Tobins Q-Ratio = 3.51 (Enterprise Value 5.76b / Total Assets 1.64b)
Interest Expense / Debt = 0.34% (Interest Expense 521k / Debt 154.8m)
Taxrate = 27.21% (28.7m / 105.4m)
NOPAT = 261.4m (EBIT 359.1m * (1 - 27.21%))
Current Ratio = 1.05 (Total Current Assets 302.6m / Total Current Liabilities 287.1m)
Debt / Equity = 0.16 (Debt 154.8m / totalStockholderEquity, last quarter 979.4m)
Debt / EBITDA = 0.19 (Net Debt 80.2m / EBITDA 423.9m)
Debt / FCF = 0.25 (Net Debt 80.2m / FCF TTM 325.5m)
Total Stockholder Equity = 1.11b (last 4 quarters mean from totalStockholderEquity)
RoA = 16.03% (Net Income 265.2m / Total Assets 1.64b)
RoE = 23.92% (Net Income TTM 265.2m / Total Stockholder Equity 1.11b)
RoCE = 28.66% (EBIT 359.1m / Capital Employed (Equity 1.11b + L.T.Debt 143.8m))
RoIC = 23.57% (NOPAT 261.4m / Invested Capital 1.11b)
WACC = 6.95% (E(5.68b)/V(5.84b) * Re(7.13%) + D(154.8m)/V(5.84b) * Rd(0.34%) * (1-Tc(0.27)))
Discount Rate = 7.13% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.92%
Shares Correlation 3-Years: -100.0 | Cagr: -4.27%
[DCF] Terminal Value 83.64% ; FCFF base≈342.5m ; Y1≈377.7m ; Y5≈487.2m
[DCF] Fair Price = 737.8 (EV 10.86b - Net Debt 80.2m = Equity 10.78b / Shares 14.6m; r=6.95% [WACC]; 5y FCF grow 11.79% → 3.0% )
EPS Correlation: -34.04 | EPS CAGR: -46.08% | SUE: -4.0 | # QB: 0
Revenue Correlation: 96.05 | Revenue CAGR: 5.10% | SUE: -4.0 | # QB: 0
EPS next Quarter (2026-06-30): EPS=5.41 | Chg7d=+0.013 | Chg30d=+0.013 | Revisions Net=+1 | Analysts=4
EPS current Year (2026-12-31): EPS=23.88 | Chg7d=+0.000 | Chg30d=-0.135 | Revisions Net=-4 | Growth EPS=+10.8% | Growth Revenue=+5.5%
EPS next Year (2027-12-31): EPS=26.62 | Chg7d=+0.000 | Chg30d=-0.210 | Revisions Net=-2 | Growth EPS=+11.5% | Growth Revenue=+6.2%
[Analyst] Revisions Ratio: +0.33 (2 Up / 1 Down within 30d for Next Quarter)
[Growth] Implied Growth Rate = 3.2% (Discount Rate 7.9% - Earnings Yield 4.7%)
[Growth] Growth Spread = +3.4% (Analyst 6.6% - Implied 3.2%)
External Resources
Dataroma Stockcircle